Hospitals call Boehringer Ingelheim’s contract pharmacy plans “appalling” while company calls for “substantial reform” of the 340B program.

Hospital Groups Outraged at Boehringer Ingelheim, Company Defends Its Plans and Calls for 340B Overhaul

Hospital trade group 340B Health has asked pharmaceutical giant Boehringer Ingelheim (BI) to withdraw its plan to cut off discounts for drugs that are distributed by contract pharmacies. As 340B Report broke on July 1, BI will stop shipping 340B-purchased drugs to hospitals’ contract pharmacies, effective Aug. 1.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report